KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) Equity Average (2023 - 2025)

Biocryst Pharmaceuticals' Equity Average history spans 8 years, with the latest figure at -$253.5 million for Q4 2025.

  • For Q4 2025, Equity Average rose 46.32% year-over-year to -$253.5 million; the TTM value through Dec 2025 reached -$253.5 million, up 46.32%, while the annual FY2025 figure was -$297.5 million, 36.11% up from the prior year.
  • Equity Average reached -$253.5 million in Q4 2025 per BCRX's latest filing, up from -$404.7 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of -$132.1 million in Q1 2023 to a low of -$475.9 million in Q2 2024.
  • Average Equity Average over 3 years is -$397.4 million, with a median of -$435.0 million recorded in 2023.
  • Peak YoY movement for Equity Average: crashed 252.59% in 2024, then soared 46.32% in 2025.
  • A 3-year view of Equity Average shows it stood at -$433.3 million in 2023, then fell by 9.0% to -$472.2 million in 2024, then skyrocketed by 46.32% to -$253.5 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Equity Average are -$253.5 million (Q4 2025), -$404.7 million (Q3 2025), and -$436.8 million (Q2 2025).